Prelude Therapeutics Incorporated(PRLD)

$5.02—

Chart

Prelude Therapeutics Incorporated(PRLD)

NASDAQ

$5.02—

Chart Studio

PRLD(PRLD)

PRLD

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.23

Aug 13, 2026 · Reports before open

Revenue Estimate

$5M

FY2029E EPS$0.28

FY2030E EPS$0.65

Analyst Sentiment

Wall St. Consensus

Hold

8 analysts·Limited coverage

Score

5 Buy (63%)1 Hold (13%)2 Sell (24%)

Rating Breakdown

Strong Buy

00%

Buy

563%

Hold

113%

Sell

225%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$8.00

+59.0%

Consensus

$8.00

+59.0%

Bull

$8.00

+59.0%

12-Month Target Range8 analysts

$8.00$8.00$8.00

Current $5.03Consensus

Current Price

$5.03

Upside to Consensus

$2.97

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+87.50%

EPS—

FY2028

Rev+146.09%

EPS—

FY2029

Rev-23.81%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$28M	$53M	$131M	$100M	$100M
Low	$3M	$53M	$16M	$12M	$12M
High	$78M	$53M	$362M	$276M	$276M
EBITDA Avg	$6M	$11M	$26M	$20M	$20M
Low	$687,120	$11M	$3M	$2M	$2M
High	$16M	$11M	$72M	$55M	$55M
EBIT Avg	$6M	$11M	$26M	$20M	$20M
Low	$687,120	$11M	$3M	$2M	$2M
High	$16M	$11M	$72M	$55M	$55M
Net Income Avg	$-23M	$-47M	$-8M	$22M	$50M
Low	$-163M	$-51M	$-18M	$-3M	$-7M
High	$7M	$-43M	$770,252	$71M	$164M
EPS Avg	$-0.65	$-0.61	$-0.07	$0.28	$0.65
Low	$-2.12	$-0.67	$-0.23	$-0.04	$-0.09
High	$0.09	$-0.56	$0.01	$0.92	$2.14
Analysts (Rev / EPS)	3 / 2	3 / 2	2 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$25M	$5M	$5M	$6M	$6M	$6M	$6M	$7M
Low	$25M	$5M	$5M	$6M	$6M	$6M	$6M	$7M
High	$25M	$5M	$5M	$6M	$6M	$6M	$6M	$7M
EBITDA Avg	$5M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
Low	$5M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
High	$5M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
EBIT Avg	$5M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
Low	$5M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
High	$5M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
Net Income Avg	$1M	$-21M	$-15M	$-17M	$-18M	$-21M	$-28M	$-29M
Low	$1M	$-21M	$-15M	$-17M	$-18M	$-21M	$-28M	$-29M
High	$1M	$-21M	$-15M	$-17M	$-18M	$-21M	$-28M	$-29M
EPS Avg	$0.01	$-0.26	$-0.18	$-0.20	$-0.22	$-0.25	$-0.34	$-0.35
Low	$0.01	$-0.26	$-0.18	$-0.20	$-0.22	$-0.25	$-0.34	$-0.35
High	$0.01	$-0.26	$-0.18	$-0.20	$-0.22	$-0.25	$-0.34	$-0.35
Analysts (Rev / EPS)	3 / 2	2 / 1	1 / 1	2 / 1	2 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Apr 27, 2026H.C. Wainwright

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

Target:$8.00

+70.2%from $4.70

Sep 10, 2024H.C. Wainwright

H.C. Wainwright Reiterates Neutral Rating on Prelude Therapeutics (PRLD)

Target:$5.00

-3.3%from $5.17

Jun 20, 2024Barclays

Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays

Target:$3.00

-22.5%from $3.87

Mar 13, 2024JMP Securities

JMP Securities Starts Prelude Therapeutics (PRLD) at Market Outperform, 'Precision Targeting of SMARCA Drives Cell Kill'

Target:$7.00

+51.5%from $4.62

Nov 17, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15

Target:$15.00

+94.8%from $7.70

Nov 15, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $10

Target:$10.00

+23.5%from $8.10

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance